19
Dec
2024
Vertex Pain Drug Fails, Puretech Delivers for IPF, Merck Dumps TIGIT, LAG3 Antibodies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Dec
2024
The Past, Present and Future of RNAi Therapies: Kevin Fitzgerald on The Long Run
Today’s guest on The Long Run is Kevin Fitzgerald. Kevin is the chief scientific officer of Cambridge, Mass.-based Alnylam Pharmaceuticals. He joined the company way back in 2005, when it was aspiring to create a new class of RNA interference medicines. These are sometimes referred to as “gene silencing” drugs. They are designed to shut down the production of disease-related... Read More
12
Dec
2024
ASH Recap, Dimension Captures $500M, & AbbVie’s New Parkinson’s Drug
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2024
Dimension Raises $500M to Seize the Tech-Driven Biology Future
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2024
ASH Highlights: Beam Base Editing, Novo’s Oral Pill Advance for Sickle Cell
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Dec
2024
Lilly Beats Novo, Amgen’s So-So Obesity Data & Atlas Stays Lean & Mean
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Dec
2024
Versant, Novo-backed Antag Gets $84M for Weight Loss Drug with Combo Potential
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Nov
2024
Meet the 2025 Timmerman Traverse for Damon Runyon Cancer Research Team
I’m excited to announce the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation team. This group of 17 men and women are on a mission to raise more than $700,000 for the next generation of outstanding cancer researchers. In April, we’ll come together on the world-famous trek to Everest Base Camp, elevation 17,600 feet. We’re raising awareness for cancer... Read More
25
Nov
2024
How to Quit Smoking and Prevent Cancer: Jonathan Bricker on The Long Run
Today’s guest on The Long Run is Jonathan Bricker. Jonathan is a professor in the cancer prevention program that’s part of the Public Health Sciences Division at Fred Hutchinson Cancer Center in Seattle. This episode is a little different than most. Jonathan is a clinical psychologist by training. His research team focuses on how to use a combination of technology... Read More
21
Nov
2024
Dr. Oz to CMS, Amgen and Pfizer Get New CSOs, & SubQ Keytruda Arrives
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Nov
2024
Startup Snapshots: A Tetra-Binder for Obesity, and a ‘Mirror Peptide’ Engine
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Nov
2024
A Tale of Two Neds: Jupiter Debuts with $70M To Invest in Startups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Nov
2024
RFK Jr. to HHS. I Was Wrong
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Nov
2024
Save the Date: TR 10th Anniversary
Hard to believe, but the 10th Anniversary of Timmerman Report is coming up in March 2025. Time to party! The past 10 years of biotechnology have been remarkable. I’m fortunate. I’ve had a front-row seat to chronicle monumental advances at Timmerman Report, and occasionally influence events. Join me and a group of biotech leaders in Boston on Mar. 6 and... Read More
12
Nov
2024
Third Rock-backed Trace Neuroscience Debuts with $101M, RNA Drug for ALS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Nov
2024
A Day to Thank Veterans
Happy Veteran’s Day. For some reason, this day doesn’t receive the same level of attention of most holidays on the American calendar. Let’s pause today to thank veterans in our communities. For real. Face to face. Or maybe on the phone. Not in a tweet. As I wrote last year: Today is a day when I honor my Dad. He... Read More
7
Nov
2024
What Will Trump Do? Look at the Record
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Nov
2024
Developing a New Class of RNA Therapeutics: Leslie Williams on The Long Run
Today’s guest on The Long Run is Leslie Williams. Leslie is the co-founder and CEO of Boston-based hC Bioscience. Her company is working to develop a new class of RNA medicines directed at transfer RNAs, also known as tRNA. The gist of the idea is to make these tRNA therapies, delivered with a lipid nanoparticle, that can carry instructions to... Read More
4
Nov
2024
Lessons from the Manure Digester
My first real journalism job flashed to mind this week. It was 1998. I was a kid reporter fresh out of the University of Wisconsin. My job was to cover Dane County government for The Capital Times, the progressive newspaper in Madison. Dane County had about 400,000 people. Half lived in the beating liberal heart of the City of Madison... Read More
31
Oct
2024
Aliada’s Mega Return, GSK & AbbVie Eye T-Cell Engagers, and IPO Scorecard
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.